Previous Close | 9.57 |
Open | 9.52 |
Bid | 9.26 x 100 |
Ask | 9.38 x 100 |
Day's Range | 9.18 - 9.65 |
52 Week Range | 6.30 - 11.92 |
Volume | |
Avg. Volume | 123,123 |
Market Cap | 263.877M |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.60 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.33 |
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Fennec Pharmaceuticals Inc (NASDAQ:FENC), a biopharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients, has reported a significant insider sell transaction.
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 13,975 shares of the company on March 26, 2024, according to a recent SEC Filing.